1887

Abstract

inhibitors of the accumulation of abnormal (protease-resistant) prion protein (PrP-res) can sometimes prolong the lives of scrapie-infected rodents. Here, transgenic mice were used to test the anti-scrapie activities of new PrP-res inhibitors, which, because they are approved drugs or edible natural products, might be considered for clinical trials in humans or livestock with transmissible spongiform encephalopathies (TSEs). These inhibitors were amodiaquine, thioridazine, thiothixene, trifluoperazine, tetrandrine, tannic acid and polyphenolic extracts of tea, grape seed and pine bark. Test compounds were administered for several weeks beginning 1–2 weeks prior to, or 2 weeks after, intracerebral or intraperitoneal 263K scrapie challenge. Tannic acid was also tested by direct preincubation with inoculum. None of the compounds significantly prolonged the scrapie incubation periods. These results highlight the need to assess TSE inhibitors active in cell culture against TSE infections prior to testing these compounds in humans and livestock.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.80082-0
2004-08-01
2019-11-21
Loading full text...

Full text loading...

/deliver/fulltext/jgv/85/8/vir852479.html?itemId=/content/journal/jgv/10.1099/vir.0.80082-0&mimeType=html&fmt=ahah

References

  1. Aguzzi, A., Glatzel, M., Montrasio, F., Prinz, M. & Heppner, F. L. ( 2001; ). Interventional strategies against prion diseases. Nat Rev Neurosci 2, 745–749.[CrossRef]
    [Google Scholar]
  2. Barret, A., Tagliavini, F., Forloni, G. & 13 other authors ( 2003; ). Evaluation of quinacrine treatment for prion diseases. J Virol 77, 8462–8469.[CrossRef]
    [Google Scholar]
  3. Beranger, F., Mange, A., Solassol, J. & Lehmann, S. ( 2001; ). Cell culture models of transmissible spongiform encephalopathies. Biochem Biophys Res Commun 289, 311–316.[CrossRef]
    [Google Scholar]
  4. Birkett, C. R., Hennion, R. M., Bembridge, D. A., Clarke, M. C., Chree, A., Bruce, M. E. & Bostock, C. J. ( 2001; ). Scrapie strains maintain biological phenotypes on propagation in a cell line in culture. EMBO J 20, 3351–3358.[CrossRef]
    [Google Scholar]
  5. Brown, P. ( 2002; ). Drug therapy in human and experimental transmissible spongiform encephalopathy. Neurology 58, 1720–1725.[CrossRef]
    [Google Scholar]
  6. Burke, K., Chandler, C. J., Starr, B. S. & Starr, M. S. ( 1990; ). Seizure promotion and protection by D-1 and D-2 dopaminergic drugs in the mouse. Pharmacol Biochem Behav 36, 729–733.[CrossRef]
    [Google Scholar]
  7. Caughey, B. & Lansbury, P. T. ( 2003; ). Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 26, 267–298.[CrossRef]
    [Google Scholar]
  8. Caughey, B. & Race, R. E. ( 1992; ). Potent inhibition of scrapie-associated PrP accumulation by Congo red. J Neurochem 59, 768–771.[CrossRef]
    [Google Scholar]
  9. Caughey, B. & Raymond, G. J. ( 1993; ). Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells. J Virol 67, 643–650.
    [Google Scholar]
  10. Caughey, W. S., Raymond, L. D., Horiuchi, M. & Caughey, B. ( 1998; ). Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines. Proc Natl Acad Sci U S A 95, 12117–12122.[CrossRef]
    [Google Scholar]
  11. Caughey, B., Horiuchi, M., Demaimay, R. & Raymond, G. J. ( 1999; ). Assays of protease-resistant prion protein and its formation. Methods Enzymol 309, 122–133.
    [Google Scholar]
  12. Collins, S. J., Lewis, V., Brazier, M., Hill, A. F., Fletcher, A. & Masters, C. L. ( 2002; ). Quinacrine does not prolong survival in a murine Creutzfeldt–Jakob disease model. Ann Neurol 52, 503–506.[CrossRef]
    [Google Scholar]
  13. Doh-ura, K., Iwaki, T. & Caughey, B. ( 2000; ). Lysosomotropic agents and cysteine protease inhibitors inhibit accumulation of scrapie-associated prion protein. J Virol 74, 4894–4897.[CrossRef]
    [Google Scholar]
  14. Dormont, D. ( 2003; ). Approaches to prophylaxis and therapy. Br Med Bull 66, 281–292.[CrossRef]
    [Google Scholar]
  15. Ehlers, B. & Diringer, H. ( 1984; ). Dextran sulphate 500 delays and prevents mouse scrapie by impairment of agent replication in spleen. J Gen Virol 65, 1325–1330.[CrossRef]
    [Google Scholar]
  16. Farquhar, C. F. & Dickinson, A. G. ( 1986; ). Prolongation of scrapie incubation period by an injection of dextran sulphate 500 within the month before or after infection. J Gen Virol 67, 463–473.[CrossRef]
    [Google Scholar]
  17. Gabizon, R., Meiner, Z., Halimi, M. & Bensasson, S. A. ( 1993; ). Heparin-like molecules bind differentially to prion proteins and change their intracellular metabolic-fate. J Cell Physiol 157, 319–325.[CrossRef]
    [Google Scholar]
  18. Gilch, S., Winklhofer, K. F., Groschup, M. H. & 7 other authors ( 2001; ). Intracellular re-routing of prion protein prevents propagation of PrPSc and delays onset of prion disease. EMBO J 20, 3957–3966.[CrossRef]
    [Google Scholar]
  19. Ingrosso, L., Ladogana, A. & Pocchiari, M. ( 1995; ). Congo red prolongs the incubation period in scrapie-infected hamsters. J Virol 69, 506–508.
    [Google Scholar]
  20. Kimberlin, R. H. & Walker, C. A. ( 1986; ). Suppression of scrapie infection in mice by heteropolyanion 23, dextran sulfate, and some other polyanions. Antimicrob Agents Chemother 30, 409–413.[CrossRef]
    [Google Scholar]
  21. Kobayashi, Y., Hirata, K., Tanaka, H. & Yamada, T. ( 2003; ). Quinacrine administration to a patient with Creutzfeldt–Jakob disease who received a cadaveric dura mater graft – an EEG evaluation. Rinsho Shinkeigaku 43, 403–408.
    [Google Scholar]
  22. Kocisko, D. A., Baron, G. S., Rubenstein, R., Chen, J., Kuizon, S. & Caughey, B. ( 2003; ). New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products. J Virol 77, 10288–10294.[CrossRef]
    [Google Scholar]
  23. Korth, C., May, B. C., Cohen, F. E. & Prusiner, S. B. ( 2001; ). Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci U S A 98, 9836–9841.[CrossRef]
    [Google Scholar]
  24. Nakajima, M., Yamada, T., Kusuhara, T., Furukawa, H., Takahashi, M., Yamauchi, A. & Kataoka, Y. ( 2004; ). Results of quinacrine administration to patients with Creutzfeldt–Jakob disease. Dement Geriatr Cogn Disord 17, 158–163.[CrossRef]
    [Google Scholar]
  25. Priola, S. A., Raines, A. & Caughey, W. S. ( 2000; ). Porphyrin and phthalocyanine anti-scrapie compounds. Science 287, 1503–1506.[CrossRef]
    [Google Scholar]
  26. Race, R. E., Caughey, B., Graham, K., Ernst, D. & Chesebro, B. ( 1988; ). Analyses of frequency of infection, specific infectivity, and prion protein biosynthesis in scrapie-infected neuroblastoma cell clones. J Virol 62, 2845–2849.
    [Google Scholar]
  27. Race, R., Oldstone, M. & Chesebro, B. ( 2000; ). Entry versus blockade of brain infection following oral or intraperitoneal scrapie administration: role of prion protein expression in peripheral nerves and spleen. J Virol 74, 828–833.[CrossRef]
    [Google Scholar]
  28. Schonberger, O., Horonchik, L., Gabizon, R., Papy-Garcia, D., Barritault, D. & Taraboulos, A. ( 2003; ). Novel heparan mimetics potently inhibit the scrapie prion protein and its endocytosis. Biochem Biophys Res Commun 312, 473–479.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.80082-0
Loading
/content/journal/jgv/10.1099/vir.0.80082-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error